Zomedica Corp Stock Price, News & Analysis

Zomedica (OTCQB: ZOMDF) announced it has earned ISO 13485:2016 certification for its manufacturing and distribution operations in Plymouth, Minnesota and Roswell, Georgia on November 6, 2025. The certification followed an independent audit validating conformity with medical device quality-management requirements across design, production, risk management, servicing, and regulatory compliance.

Management said the certification strengthens quality infrastructure, supports global market readiness and regulatory filings, enhances customer and partner confidence, promotes operational efficiency, and positions Zomedica to scale diagnostics and therapeutics — including potential products for the human health market.

Zomedica (OTCQB:ZOMDF) reported record third quarter results for the period ended September 30, 2025, with revenue up 16% to $8.1 million and a 67% gross margin. Diagnostics revenue rose 51% and new Development Services contributed $0.7M this quarter. Operating expenses fell $0.5M sequentially to $12.0M, driving a lower net loss of $6.1M and an improved Adjusted Non-GAAP EBITDA loss of $3.7M. The company ended the quarter with $54.4M in cash and securities and 979,949,668 shares outstanding.

Zomedica (OTCQB:ZOMDF) launched the Assisi Loop Lounge, a full-body targeted pulsed electromagnetic field (tPEMF) therapy bed for small animals with unlimited uses and a lifetime warranty, positioned for clinic and at-home use for osteoarthritis, chronic pain, post-surgical recovery, hospice care, and travel.

The product is promoted as peer-reviewed and evidence-backed, available through veterinarians, select retailers, and directly from Zomedica. Company highlights include 2024 revenue of $27M (+8% YoY), approximately $59M liquidity as of June 30, 2025, and cited global tPEMF market size of $400–500M in 2025 with an 8–10% CAGR to 2031.

Zomedica (OTCQB:ZOMDF) announced a Fourth Friday at Four webinar on October 24, 2025 at 4:00 p.m. ET to showcase the VETGuardian Zero Touch monitoring platform.

The session will review how the VETGuardian monitor uses radar and imaging technology to capture continuous vital signs—heart rate, respiration, and body temperature—without wires or contact. The release cites a $720 million veterinary monitoring market in 2025, projected to grow at ~8% annually through 2029, and positions VETGuardian as a workflow- and welfare-improving tool that complements Zomedica's diagnostics and therapeutics.

The webinar is offered via live webcast and registration details are available on the company website.

Zomedica (OTCQB:ZOMDF) has expanded its TRUFORMA diagnostic platform by adding feline testing capability to its cobalamin & folate assay, previously only available for canine patients. The multiplexed assay, which combines two critical tests in one, delivers results in under 25 minutes at the point of care.

Originally launched for dogs in early 2024, this first-of-its-kind in-clinic test now addresses the critical need for rapid diagnosis in feline patients with gastrointestinal conditions. According to veterinary experts, this expansion is particularly significant as feline patients with GI disease often deteriorate more rapidly than canine patients, making quick results crucial for timely treatment.

Zomedica (OTCQB:ZOMDF) has strengthened its intellectual property portfolio with four new U.S. patents for its TRUVIEW and TRUFORMA diagnostic platforms. Three patents relate to the TRUVIEW Microscope's automated slide processing systems, while the fourth patent protects acoustic wave sensor technology with crowding agents.

The company now holds 83 U.S. patents and 145 international patents, along with 37 U.S. and 116 foreign trademarks. These innovations position Zomedica to compete in the veterinary diagnostics market, currently valued at $8-11 billion and projected to reach $17-22 billion by 2030-2032, growing at a 9-11% CAGR.

Zomedica (OTCQB:ZOMDF) announces its upcoming Fourth Friday at Four webinar on September 26, 2025 at 4:00 PM ET, featuring their TRUVIEW digital cytology microscope. The webinar will showcase how TRUVIEW is revolutionizing veterinary diagnostics by enabling the creation of automated laboratory-quality blood films from fresh blood samples.

The TRUVIEW system addresses historical challenges in veterinary practices by eliminating technical barriers to blood film preparation, allowing clinics to return to gold-standard protocols. The technology uniquely enables blood film analysis before cell bloat occurs from EDTA preservatives, marking a significant advancement in point-of-care diagnostics.

Zomedica (OTCQB:ZOMDF) has expanded its distribution agreement with UXR Inc. to strengthen its presence in the Canadian veterinary market. Under the agreement, UXR becomes the exclusive distributor of Zomedica's PulseVet® system and VETGuardian® products in Canada, along with distribution rights for the Assisi® product portfolio.

The expansion targets a market of over 4,000 veterinary practices in Canada, with a projected 7% compound annual growth rate. The partnership aims to enhance access to Zomedica's innovative therapeutic and monitoring solutions for the country's 28 million pets, focusing on technologies that reduce pain, improve recovery, and enhance monitoring in veterinary practices.

Zomedica (OTCQB:ZOMDF) has announced a strategic distribution partnership with Pioneer Veterinary Products Limited to strengthen its presence in the UK veterinary market. The agreement initially focuses on distributing Zomedica's TRUFORMA® diagnostic platform across England, Scotland, Wales, and Northern Ireland, with plans to later introduce VETGuardian® remote monitoring technology.

Pioneer will serve as an exclusive distributor for the small animal market and a non-exclusive distributor for equine products. The TRUFORMA platform provides reference lab-quality results for diagnosing endocrine and thyroid conditions in dogs, cats, and horses, while VETGuardian offers wireless, contactless monitoring of animal vitals in surgical and post-operative care settings.